About

Jay P. Shepard

Jay P. Shepard

Chief Executive Officer

Jay P. Shepard

Jay has more than 33 years of experience across pharmaceutical, biotechnology and drug delivery companies, most recently as President and Chief Executive Office of Versartis, where he was also a member of the Board of Directors. Previously, Jay was an Executive Partner at Sofinnova Ventures, a healthcare-focused venture capital firm, where he leveraged his industry expertise in support of the firm’s portfolio companies.
Prior to that, he was President and CEO of NextWave Pharmaceuticals, a pediatric-focused company acquired by Pfizer; President and CEO of Ilypsa, a nephrology company acquired by Amgen. Jay has served on the board of directors of numerous public and private companies, including Ilypsa, Relypsa, Inc. and Intermune, Inc., and currently serves on the board of directors of Bullet Biotechnology, Inc., Marinus Pharmaceuticals, Inc., and Durect Corporation. Jay has extensive commercial experience, helping lead over 17 product launches and establishing and coordinating multiple sales and marketing operations. He previously served as Vice President of Commercial Operations at Telik, where he oversaw all commercialization and market planning activities for the company’s oncology programs. Jay was one of the early commercial executives at Alza Pharmaceuticals, where he was Vice President in the Commercial Operations group, having held leadership roles of increasing responsibility in its establishment, operations and commercial presence. Alza was acquired by Johnson & Johnson in late 2001. He began his career in the pharmaceutical industry at Johnson & Johnson and Syntex Labs. Jay is a board member of Esperion Therapeutics, the Christopher & Dana Reeves Foundation and the Santa Clara University Entrepreneurial School. Jay holds a BS in Business Administration from the University of Arizona.